Bristol Myers Squibb's 4% dividend looks secure despite 2027 sales drop and heavy debt.

Bristol Myers Squibb offers a 4.08% dividend yield supported by solid earnings and cash flow, with a payout ratio around 40%. The company faces a significant $1.5-$2 billion sales drop in 2027 due to the Eliquis patent cliff but is offsetting losses with growth in other areas and cost savings. Debt is high at $44.8 billion but trending down from previous years. Management prioritizes dividends while balancing debt reduction and business development, suggesting the dividend is sustainable though growth may slow. Investors should watch upcoming clinical data for future catalysts.

Bristol Myers Squibb's dividend outlook comes as the stock trades at USD 63.44 on Pluang, showing a 1.17% decline in the past day as of Nov 07, 2026 04:02 WIB. The dividend yield on Pluang stands at 3.99%, slightly below the article's 4.08%, while the market cap is $129.04 billion. Investors on Pluang are currently all buyers, reflecting confidence despite recent price pressure.